H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Leap Therapeutics (LPTX – Research Report) today and set a price target of $7.00. The company’s shares closed yesterday at $2.40.
According to TipRanks, Ramakanth is an analyst with an average return of -22.3% and a 21.24% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Affimed, Vor Biopharma, and ImmunoGen.
Leap Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $18.50, representing a 670.83% upside. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $20.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $18.60 and a one-year low of $2.11. Currently, Leap Therapeutics has an average volume of 266.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01 and TRX518. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
Read More on LPTX:
- Leap Therapeutics Reports Second Quarter 2023 Financial Results
- LPTX Upcoming Earnings Report: What to Expect?
- Leap Therapeutics initiates Part B of the DeFianCe study of DKN-01
- Biotech Alert: Searches spiking for these stocks today
- Leap Therapeutics price target lowered to $17 from $20 at Raymond James
